1 terminated, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Pharmascience Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19 Isoquercetin (IQC-950AN) - COVID-19 | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2022-01-01 | 2025-03-24 | |
| Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome Enteric-Coated Cholestyramine (ECC) Capsule, Placebo - Short Bowel Syndrome | Phase 2 | Terminated | Pharmascience Inc. | 13 | 2019-10-15 | 2022-07-19 |
COVID-19 (1) · Short Bowel Syndrome (1)
Capsules (1) · isoquercitrin (1)
Poland (1)
Kinga Szczepanek, MD (1) · Konrad Matysiak, MD, PhD (1) · Marek Kunecki, MD, PhD (1)
2018 (1)